Henan Medinno Pharmaceutical Technology Co. Ltd. has synthesized TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer, aging, arteriosclerosis, diabetic nephropathy, Alzheimer’s disease, viral infections, osteoporosis and skin fibrosis, among others.